Results 121 to 130 of about 26,603 (276)

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran   +3 more
wiley   +1 more source

Differential Sensitivity of Maize Hybrids to Nicosulfuron

open access: yesAgronomy
Maize hybrids exhibit varying levels of tolerance to the herbicide nicosulfuron, influenced by the environment, plant developmental stage, and herbicide rate.
Natalia da Cunha Bevilaqua   +6 more
doaj   +1 more source

Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011–2014

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Metformin, the first‐line treatment for Type 2 diabetes mellitus (T2DM), may be neuroprotective but also lowers serum vitamin B12 by ~19%, raising concern that B12 depletion could offset this benefit. We used modern exploratory causal mediation methods in a nationally representative sample to test whether vitamin B12 and methylmalonic ...
Danial Fotros   +2 more
wiley   +1 more source

Enzymatic Properties and Ryegrass Resistance Mechanism to Iodosulfuron-Methyl-Sodium Herbicide

open access: yesPlanta Daninha
: Ryegrass(Lolium multiflorum)is one of the most worrisome species with regard to herbicide resistance. This study aimed at characterizing the acetolactate synthase (ALS) enzyme activity of resistant biotypes (NC and AR) and susceptible biotypes to
F. MARIANI   +5 more
doaj   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu   +6 more
wiley   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang   +9 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos   +5 more
wiley   +1 more source

Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives

open access: yes, 2011
OBJECTIVE Numerous studies have suggested a decreased risk of cancer in patients with diabetes on metformin. Because different comparison groups were used, the effect magnitude is difficult to estimate. Therefore, the
Bruno H.Ch. Stricker   +8 more
core   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

open access: yesImmunology, EarlyView.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy